Avzivi (bevacizumab-tnjn) / Bio-Thera Solutions, Cipla, BeOne Medicines, Biomm, Mega Lifesciences, Sandoz - LARVOL DELTA

A phase 2 study of tislelizumab combined with bevacizumab and chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancer. (PubMed, EClinicalMedicine) - P2 | "Patients received tislelizumab (200 mg), bevacizumab (7.5 mg/kg), paclitaxel (175 mg/m2), and cisplatin (50 mg/m2) or carboplatin (AUC = 5) on day 1 of cycle 1 (every 3 weeks) in safety run-in stage. This work was supported by grants from the Pioneer R&D Program of Zhejiang (2023SDYXS0001, 2022C03031) and by BeiGene (Beijing) Co., Ltd. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript."

Journal • P2 data • Cervical Cancer • Hematological Disorders • Oncology • Renal Disease • Solid Tumor

Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma. (PubMed, Front Immunol) - P2, P2/3 | "Sensitivity analysis by two different methods supported the findings from the primary MAIC analysis. This MAIC analysis demonstrated that tislelizumab plus lenvatinib achieved superior efficacy, with higher ORR and longer PFS and OS compared to sintilimab plus bevacizumab biosimilar in untreated Chinese patients with uHCC."

Clinical • Journal • Hepatocellular Cancer • Oncology • Solid Tumor • PD-L1

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases (clinicaltrials.gov) - P2 | N=7 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | N=112 ➔ 7 | Trial completion date: Jul 2025 ➔ Jul 2026 | Trial primary completion date: Jul 2025 ➔ Feb 2025

Enrollment change • Trial completion date • Trial primary completion date • Brain Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Primary efficacy and safety results of BAT1308, a PD-1 inhibitor, + chemotherapy ± bevacizumab in phase 2 trial for persistent, recurrent, or metastatic cervical cancer. (ASCO 2025) - P2/3 | "Patients received BAT1308 (300 mg Q3W for up to 24 months) plus platinum-based chemotherapy (paclitaxel 175 mg/m2 + cisplatin 50 mg/ m2 or carboplatin AUC 5) and, per investigator discretion, bevacizumab (15 mg/kg). BAT1308 combined with platinum-based chemotherapy ± Bevacizumab as first-line therapy showed durable anti-tumor activity and manageable safety profile for PD-L1-positive (CPS ≥ 1) persistent, recurrent or metastatic cervical cancer. These data are consistent with the earlier results and provide support for further studies."

Clinical • Metastases • P2 data • Alopecia • Anemia • Cervical Cancer • Immunology • Neutropenia • Oncology • Solid Tumor • Squamous Cell Carcinoma • Thrombocytopenia

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer (clinicaltrials.gov) - P1/2 | N=0 | Withdrawn | Sponsor: National Cancer Institute (NCI) | N=127 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Carcinosarcoma • Epithelial Ovarian Cancer • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Refractory Ovarian Cancer • Sarcoma • Solid Tumor

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (clinicaltrials.gov) - P2 | N=349 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2025 ➔ Mar 2026

Trial completion date • Carcinosarcoma • Endometrial Adenocarcinoma • Endometrial Cancer • Endometrial Serous Adenocarcinoma • Oncology • Sarcoma • Solid Tumor • Uterine Cancer • AKT1

Liberty-201: A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov) - P1/2 | N=113 | Active, not recruiting | Sponsor: BeiGene | Trial completion date: Apr 2026 ➔ Dec 2026 | Trial primary completion date: Apr 2026 ➔ May 2025

Mismatch repair • pMMR • Trial completion date • Trial primary completion date • Colorectal Cancer • Oncology • Solid Tumor • PD-L1

NRG-GY036: Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer (clinicaltrials.gov) - P3 | N=880 | Recruiting | Sponsor: NRG Oncology | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2035 ➔ Dec 2034

Enrollment open • Trial completion date • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • BRCA

External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer (clinicaltrials.gov) - P1/2 | N=35 | Not yet recruiting | Sponsor: Jonsson Comprehensive Cancer Center | Trial completion date: Jan 2031 ➔ Jan 2032 | Initiation date: Jan 2025 ➔ Jan 2026 | Trial primary completion date: Jan 2030 ➔ Jan 2031

Trial completion date • Trial initiation date • Trial primary completion date • Cervical Adenocarcinoma • Cervical Cancer • Cervical Squamous Cell Carcinoma • Oncology • Solid Tumor • Squamous Cell Carcinoma

ECOG-ACRIN EA3202: Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (clinicaltrials.gov) - P2/3 | N=430 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Recruiting ➔ Active, not recruiting

Checkpoint inhibition • Enrollment closed • IO biomarker • Head and Neck Cancer • Hypopharyngeal Cancer • Laryngeal Cancer • Lung Cancer • Nasopharyngeal Carcinoma • Oncology • Oral Cancer • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Squamous Cell Skin Cancer • PD-L1

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting | Trial completion date: Oct 2025 ➔ Dec 2026 | Initiation date: Apr 2025 ➔ Jan 2026 | Trial primary completion date: Oct 2025 ➔ Dec 2026

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Solid Tumor

NRG-GY009: Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - P2/3 | N=444 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Sep 2026 ➔ Mar 2026

Platinum resistant • Trial completion date • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • PD-L1

BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov) - P3 | N=430 | Enrolling by invitation | Sponsor: BeiGene | N=300 ➔ 430

Enrollment change • Oncology • Solid Tumor

ECOG-ACRIN 5103: Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer (clinicaltrials.gov) - P3 | N=4994 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Feb 2025 ➔ Feb 2026

Trial completion date • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2

CALGB 40603: Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - P2 | N=454 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Feb 2025 ➔ Feb 2026

Trial completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Inflammatory Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • PGR

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer (clinicaltrials.gov) - P3 | N=50 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2025 ➔ Mar 2026

Trial completion date • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Solid Tumor

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - P3 | N=403 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Feb 2025 ➔ Feb 2026

Trial completion date • Head and Neck Cancer • Hypopharyngeal Cancer • Lung Cancer • Oncology • Oral Cancer • Oropharyngeal Cancer • Salivary Gland Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Squamous Cell Carcinoma of Unknown Primary • Tongue Carcinoma

Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study (clinicaltrials.gov) - P3 | N=120 | Suspended | Sponsor: National Cancer Institute (NCI) | Recruiting ➔ Suspended

Trial suspension • Colon Adenocarcinoma • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Microsatellite Instability • Oncology • Solid Tumor • MLH1 • MSH2 • MSH6 • MSI

S0533: Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - P2 | N=29 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Feb 2025 ➔ Feb 2026

Trial completion date • Large Cell Carcinoma • Lung Adenocarcinoma • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (clinicaltrials.gov) - P2 | N=88 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: May 2025 ➔ Dec 2025 | Trial primary completion date: May 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Psoriatic Arthritis • Solid Tumor • IL2

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery (clinicaltrials.gov) - P3 | N=1501 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed | Trial completion date: Oct 2025 ➔ Jan 2025

Trial completion • Trial completion date • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer (clinicaltrials.gov) - P2 | N=65 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2024 ➔ Dec 2027 | Trial primary completion date: Dec 2024 ➔ Dec 2027

Trial completion date • Trial primary completion date • Genito-urinary Cancer • Kidney Cancer • Oncology • Papillary Renal Cell Carcinoma • Renal Cell Carcinoma • Solid Tumor

NRG-GY009: Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - P2/3 | N=444 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Sep 2024 ➔ Sep 2026

Trial completion date • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • PD-L1

SWOG-S0518: Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor (clinicaltrials.gov) - P3 | N=427 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jan 2025 ➔ Jan 2026

Trial completion date • Endocrine Cancer • Gastric Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma

BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer (clinicaltrials.gov) - P2/3 | N=526 | Recruiting | Sponsor: Bio-Thera Solutions | Not yet recruiting ➔ Recruiting | Trial completion date: Aug 2024 ➔ Jan 2027 | Trial primary completion date: Apr 2024 ➔ Sep 2026

Enrollment open • Trial completion date • Trial primary completion date • Cervical Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • PD-L1